A detailed history of State Street Corp transactions in Vera Therapeutics, Inc. stock. As of the latest transaction made, State Street Corp holds 2,350,727 shares of VERA stock, worth $89.3 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,350,727
Previous 2,181,058 7.78%
Holding current value
$89.3 Million
Previous $33.5 Million 202.18%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$14.91 - $49.14 $2.53 Million - $8.34 Million
169,669 Added 7.78%
2,350,727 $101 Million
Q4 2023

Feb 14, 2024

BUY
$9.29 - $16.0 $4.21 Million - $7.25 Million
453,412 Added 26.24%
2,181,058 $33.5 Million
Q3 2023

Nov 14, 2023

BUY
$13.71 - $19.64 $15.8 Million - $22.6 Million
1,151,097 Added 199.65%
1,727,646 $23.7 Million
Q2 2023

Aug 14, 2023

BUY
$6.11 - $17.83 $1.66 Million - $4.86 Million
272,402 Added 89.56%
576,549 $9.25 Million
Q1 2023

May 15, 2023

BUY
$5.41 - $18.3 $256,709 - $868,353
47,451 Added 18.49%
304,147 $2.36 Million
Q4 2022

Feb 14, 2023

BUY
$15.74 - $22.19 $108,810 - $153,399
6,913 Added 2.77%
256,696 $4.97 Million
Q3 2022

Nov 15, 2022

BUY
$13.27 - $22.31 $365,296 - $614,149
27,528 Added 12.39%
249,783 $5.32 Million
Q2 2022

Aug 15, 2022

BUY
$12.82 - $23.4 $685,844 - $1.25 Million
53,498 Added 31.7%
222,255 $3.03 Million
Q1 2022

May 16, 2022

BUY
$17.8 - $28.06 $809,615 - $1.28 Million
45,484 Added 36.9%
168,757 $3.96 Million
Q4 2021

Feb 14, 2022

BUY
$15.01 - $35.8 $720,750 - $1.72 Million
48,018 Added 63.81%
123,273 $3.29 Million
Q3 2021

Nov 15, 2021

BUY
$13.71 - $30.6 $1.03 Million - $2.3 Million
75,255 New
75,255 $1.31 Million

Others Institutions Holding VERA

About Vera Therapeutics, Inc.


  • Ticker VERA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 27,042,300
  • Market Cap $1.03B
  • Description
  • Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with ...
More about VERA
Track This Portfolio

Track State Street Corp Portfolio

Follow State Street Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

News

Stay updated on State Street Corp with notifications on news.